EsoBiotec's platform, EsoBiotec Engineered NanoBody Lentiviral (ENaBL), uses lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which program them to recognize and destroy tumor cells for cancer treatment or autoreactive cells for potential use in immune-mediated diseases. This approach enables cell therapies to be administered through an IV injection and without the need for immune-cell depletion, according to information from AstraZeneca.